Your shopping cart is currently empty

Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic that is specifically designed to actively suppress hepatic production of apolipoprotein C-III (APOC3), a critical structural and functional component of triglyceride-rich lipoproteins (TRLs) and a central regulator of systemic triglyceride metabolism, thereby addressing dyslipidemia at the level of gene expression through targeted post-transcriptional silencing mechanisms.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $221 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $442 | 2-4 weeks | 2-4 weeks |
| Description | Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic that is specifically designed to actively suppress hepatic production of apolipoprotein C-III (APOC3), a critical structural and functional component of triglyceride-rich lipoproteins (TRLs) and a central regulator of systemic triglyceride metabolism, thereby addressing dyslipidemia at the level of gene expression through targeted post-transcriptional silencing mechanisms. |
| Synonyms | ARO-APOC3 |
| Molecular Weight | 15618.77 |
| Cas No. | 2379776-40-4 |
| Relative Density. | no data available |
| Storage | Lyophilized powder: -20~-80°C for 1 year |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.